CGEM News and Press, Cullinan Oncology Inc. From 07/05/22

CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that its Chief Scientific Officer, P...

Cullinan Oncology receives upfront cash payment of $275 million, with potential to receive up to an additional $130 million in regulatory-based milestone payments Taiho obtains exclusive global rights to CLN-081/TAS6417 outside the U.S.; Taiho and Cullinan Oncology to jointly de...

Cullinan Oncology (CGEM) has disclosed a $8.3M share buy by 10% owner, BVF Partners. BVF Partners bought 751,396 shares of the company's common stock at $11.00. Shares are currently up ~4%. For further details see: Cullinan Oncology discloses $8.3M share buy by insid...

Cullinan Oncology (NASDAQ:CGEM) granted stock options to buy 174K common shares to four employees outside the company. The equity awards were granted as an inducement material according to the company's 2021 Option and Incentive Plan. The stock options were granted as an inducement mater...

Updated data from Phase 1/2a study show median duration of response greater than 21 months and median progression-free survival of 12 months at 100 mg BID dose Confirmed overall response rate of 41% at 100 mg BID dose Continued favorable safety and tolerability...

Meeting to highlight updated data from the Phase 1/2a study of CLN-081 CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapie...

CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that its Chief Financial Officer, Jef...

Cullinan Oncology (NASDAQ:CGEM) gained 11.76% in value after the biotechnology company disclosed securities acquisition by BVF Partners. Director and 10% Owner BVF Partners acquired ~1.11M shares at an average price of $9.11 in multiple transactions. BVF now owns ~12.92M of direct owners...

Cullinan Oncology press release (NASDAQ:CGEM): Q1 GAAP EPS of -$0.27 beats by $0.28.  Cash and investments were $410 million as of March 31, 2022. Including the $275 million upfront payment related to the Taiho transaction, the company expect to have $685 million in cash and investm...

Announced U.S. co-development and co-commercialization agreement for CLN-081 with Taiho Pharmaceutical; updated CLN-081 data accepted for oral presentation at the American Society for Clinical Oncology (ASCO) meeting in June CLN-049 and CLN-619 Phase I dosing continues with init...